Furthermore, CCAR2 is associated with an immunosuppressive tumor microenvironment in basal-like TNBC, fostering an immune-evasive phenotype that correlates with a poorer predicted response to immunotherapy.<h4>Conclusion</h4>We constructed an ARG-based prognostic signature for TNBC and identified CCAR2 as a key metastatic driver that confers anoikis resistance, immune evasion, and stemness. This evidence concerns the gene CCAR2 and neoplasm.